A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss. Article

Full Text via DOI: 10.1200/JCO.2019.37.4_suppl.TPS730 Web of Science: 000489107600048

Cited authors

  • Sharma, Sunil; Becerra, Carlos Roberto; Matrana, Marc Ryan; Alistar, Angela Tatiana; Chiorean, E. Gabriela; Schmid, Anita Nagypal; Grigorian, Berta; Hou, Shihe; Desai, Neil

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0732-183X


  • 37


  • 4